MX9203629A - Composiciones de anticuerpos monoclonales para el tratamiento profilactico o terapeutico de infecciones bacterianas debidas a estreptococos del grupo b. - Google Patents

Composiciones de anticuerpos monoclonales para el tratamiento profilactico o terapeutico de infecciones bacterianas debidas a estreptococos del grupo b.

Info

Publication number
MX9203629A
MX9203629A MX9203629A MX9203629A MX9203629A MX 9203629 A MX9203629 A MX 9203629A MX 9203629 A MX9203629 A MX 9203629A MX 9203629 A MX9203629 A MX 9203629A MX 9203629 A MX9203629 A MX 9203629A
Authority
MX
Mexico
Prior art keywords
streptococces
prophylactic
group
monoclonal antibodies
therapeutic treatment
Prior art date
Application number
MX9203629A
Other languages
English (en)
Spanish (es)
Inventor
Howard V Raff
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX9203629A publication Critical patent/MX9203629A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX9203629A 1986-02-07 1992-06-26 Composiciones de anticuerpos monoclonales para el tratamiento profilactico o terapeutico de infecciones bacterianas debidas a estreptococos del grupo b. MX9203629A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82800586A 1986-02-07 1986-02-07
US94449586A 1986-12-19 1986-12-19

Publications (1)

Publication Number Publication Date
MX9203629A true MX9203629A (es) 1992-07-01

Family

ID=27125154

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9203629A MX9203629A (es) 1986-02-07 1992-06-26 Composiciones de anticuerpos monoclonales para el tratamiento profilactico o terapeutico de infecciones bacterianas debidas a estreptococos del grupo b.

Country Status (28)

Country Link
US (2) US5717071A (enExample)
JP (1) JP2645343B2 (enExample)
KR (1) KR870007697A (enExample)
CN (1) CN87102167A (enExample)
AT (1) AT398781B (enExample)
BE (1) BE1000967A5 (enExample)
CA (1) CA1339013C (enExample)
CH (1) CH672072A5 (enExample)
DE (1) DE3703711A1 (enExample)
DK (1) DK63187A (enExample)
ES (1) ES2009140A6 (enExample)
FI (1) FI94489C (enExample)
FR (1) FR2595946B1 (enExample)
GB (1) GB2186592B (enExample)
GR (1) GR870194B (enExample)
HK (1) HK21795A (enExample)
HU (1) HU203583B (enExample)
IE (1) IE59627B1 (enExample)
IL (1) IL81370A (enExample)
IT (1) IT1207589B (enExample)
LU (1) LU86761A1 (enExample)
MX (1) MX9203629A (enExample)
NL (1) NL8700286A (enExample)
NO (1) NO176924C (enExample)
NZ (2) NZ233920A (enExample)
OA (1) OA08477A (enExample)
PT (1) PT84258B (enExample)
SE (1) SE468747B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0256713A3 (en) * 1986-08-06 1989-02-15 Merck & Co. Inc. Therapeutic human antipseudomonas aeruginosa antibodies
CA1341375C (en) * 1988-10-12 2002-07-09 Baxter International Inc. Compositions and methods for the treatment and prevention of gram-negative bacterial infections
DE3925161A1 (de) * 1989-03-15 1990-09-27 Boehringer Mannheim Gmbh Monoklonale, gegen eca gerichtete antikoerper und ihre verwendung
JPH0329196A (ja) * 1989-05-09 1991-02-07 Advanced Micro Devicds Inc センス増幅器
US6315999B1 (en) 1989-08-10 2001-11-13 Solvay, S.A. Pharmaceutical product for the treatment of sepsis
GB8918232D0 (en) * 1989-08-10 1989-09-20 Opal Stephen M Pharmaceutical product for the treatment of septic shock
US20080139789A1 (en) * 1990-10-22 2008-06-12 Henry M. Jackson Foundation For The Advancement Of Military Medicine Isolated Broadly Reactive Opsonic Immunoglobulin for Treating a Pathogenic Coagulase-Negative Staphylococcus Infection
PT635132E (pt) * 1992-03-19 2001-03-30 Henry M Jackson Found Advanc M Anticorpos opsonicos amplamente reactivos que reagem com antigenios de estafilococos comuns
JPH08508240A (ja) * 1993-01-12 1996-09-03 ジョージ グリスティーナ，アンソニー 受動免疫の直接的濃厚伝達のための方法および組成物
US5510264A (en) * 1993-09-28 1996-04-23 Insight Biotech Inc. Antibodies which bind meningitis related homologous antigenic sequences
WO1999054357A1 (en) * 1998-04-14 1999-10-28 Chugai Research Institute For Molecular Medicine, Inc. Novel cytokine-like protein
US8337846B2 (en) * 2007-07-23 2012-12-25 Sanofi Pasteur Limited Immunogenic polypeptides and monoclonal antibodies
CN104861066B (zh) * 2009-03-23 2018-05-08 夸克制药公司 治疗癌症和纤维化疾病的化合物组合物和方法
CN103501808A (zh) 2010-12-03 2014-01-08 赛诺菲巴斯德有限公司 用于针对肺炎链球菌免疫的组合物
AU2016353073A1 (en) * 2015-11-10 2018-06-07 Visterra, Inc. Antibody molecule-drug conjugates that specifically binds to lipopolysaccharide and uses thereof
EP3571223B1 (en) 2017-01-18 2024-09-18 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
AU2021248643A1 (en) 2020-04-03 2022-10-27 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464465A (en) * 1982-04-05 1984-08-07 Genetic Systems Corporation Cell-driven viral transfer in eukaryotes
AU567693B2 (en) * 1982-09-30 1987-12-03 University Of Rochester Human monoclonal antibodies against bacterial toxins
US4587121A (en) * 1983-06-14 1986-05-06 Miles Laboratories, Inc. High titer Pseudomonas immune serum globulin
US5179018A (en) * 1983-10-14 1993-01-12 Centocor, Inc. Mamalian monoclonal antibodies against endotoxin of gram-negative bacteria
US4834975A (en) * 1984-05-25 1989-05-30 Genetics Corporation Human monoclonal antibodies to serotypic lipopolysaccharide determinants on gram-negative bacteria and their production
DE3426903A1 (de) * 1984-07-20 1986-01-23 Biotest Pharma GmbH, 6000 Frankfurt Eine immunglobulinpraeparation in kombination mit einer anderen pharmakologisch wirksamen praeparation zur verwendung bei der behandlung von krankheiten
US4675287A (en) * 1984-07-26 1987-06-23 Scripps Clinic And Research Foundation Monoclonal antibody directed to human ganglioside GD2
US4677070A (en) * 1985-04-26 1987-06-30 Cetus Corporation Pseudomonas aeruginosa exotoxin A antibodies, their preparation and use
US4772464A (en) * 1985-08-01 1988-09-20 Miles Laboratories, Inc. Protective antibodies to serotypic determinants of flagellar antigens
US4777136A (en) * 1985-09-27 1988-10-11 The Regents Of The University Of California Monoclonal antibody reactive with Pseudomonas Aeruginosa
US4918163A (en) * 1985-09-27 1990-04-17 Pfizer Inc. Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria
NZ218499A (en) * 1985-12-10 1990-04-26 Genetic Systems Corp Monoclonal antibodies against pseudomonas aeruginosa, pharmaceutical compositions and detection methods
US4970070A (en) * 1986-02-07 1990-11-13 Genetic Systems Corporation Protective monoclonal antibody compositions for infections due to group B streptococcus

Also Published As

Publication number Publication date
NZ219187A (en) 1990-12-21
HU203583B (en) 1991-08-28
CN87102167A (zh) 1988-02-03
IL81370A (en) 1991-06-30
DE3703711C2 (enExample) 1993-06-24
NO870476L (no) 1987-08-10
FI94489B (fi) 1995-06-15
JPS62270535A (ja) 1987-11-24
NL8700286A (nl) 1987-09-01
DE3703711A1 (de) 1987-09-24
OA08477A (fr) 1988-07-29
GB2186592A (en) 1987-08-19
IE59627B1 (en) 1994-03-09
PT84258A (en) 1987-03-01
JP2645343B2 (ja) 1997-08-25
FR2595946B1 (fr) 1991-10-04
DK63187D0 (da) 1987-02-06
HK21795A (en) 1995-02-24
PT84258B (pt) 1989-09-14
NO176924B (no) 1995-03-13
GB8702689D0 (en) 1987-03-11
AT398781B (de) 1995-01-25
GB2186592B (en) 1990-08-01
US5837541A (en) 1998-11-17
SE8700467D0 (sv) 1987-02-06
ATA26287A (de) 1994-06-15
FI870502A0 (fi) 1987-02-06
IL81370A0 (en) 1987-08-31
IE870320L (en) 1987-08-07
CA1339013C (en) 1997-03-25
SE8700467L (sv) 1987-08-08
NZ233920A (en) 1990-12-21
LU86761A1 (fr) 1987-09-15
NO870476D0 (no) 1987-02-06
DK63187A (da) 1987-08-08
KR870007697A (ko) 1987-09-21
FI94489C (fi) 1995-09-25
HUT46062A (en) 1988-09-28
SE468747B (sv) 1993-03-15
FR2595946A1 (fr) 1987-09-25
US5717071A (en) 1998-02-10
GR870194B (en) 1987-06-10
BE1000967A5 (fr) 1989-05-30
FI870502L (fi) 1987-08-08
ES2009140A6 (es) 1989-09-01
IT8719292A0 (it) 1987-02-06
IT1207589B (it) 1989-05-25
CH672072A5 (enExample) 1989-10-31
NO176924C (no) 1995-06-21

Similar Documents

Publication Publication Date Title
MX9203629A (es) Composiciones de anticuerpos monoclonales para el tratamiento profilactico o terapeutico de infecciones bacterianas debidas a estreptococos del grupo b.
NO834146L (no) Fremgangsmaate for fremstilling av epimert azahomoerytromycin a
MA22842A1 (fr) Procede de preparation de compositions de vaccin.
FI873113L (fi) Tvaettmedelskomposition.
FI840219L (fi) Human-humanhybridom foer neoplasmer.
AR194587A1 (es) Procedimiento para la preparacion de 2,2'metilendifenoles sustituidos
NO871715L (no) Fremgangsmaate for fremstilling av alfa-olefinpolymer.
ES2013631B3 (es) Metodo para el tratamiento de tejidos.
BE795950A (fr) Procede de preparation d'amidosilanes
IT8119673A0 (it) Composizioni farmaceutiche per il trattamento di osteopatie.
DK550586D0 (da) Laegemiddel til behandling af neuropsykiatriske tilstande, saasom demens
FR2664274B1 (fr) Procede de preparation de sulfates cycliques.
ES518181A0 (es) Procedimiento para la preparacion de inmunoglobulina administrable por via intravenosa.
FI831192A7 (fi) Menetelmä substituoitujen 2- aminobentsimidatsolien valmistamiseksi.
FI874414A0 (fi) Kontrollerat frigoerande farmaceutiska kompositioner.
IT7924246A0 (it) Procedimento per la purificazione di resorcina grezza.
FI933755A7 (fi) Menetelmä trans-piperidiini-2,5-dikarboksylaattien valmistamiseksi
FI872459A7 (fi) Farmaseuttinen valmiste bakteeri-infektioiden hoitoon.
ES2019594B3 (es) Metodo de tamponado del ph.
IT8319024A0 (it) Composizione medicinale per il trattamento di certe neurovirosi.
BE748297A (fr) Enzymes et methode pour la preparation, l'isolement et la purification de ces enzymes
IT8123052A0 (it) Procedimento per la preparazione di trattamento di pozzi.
BE790056A (fr) Procede de preparation de 1, 1'-dianthraquinonyles
ES2019583B3 (es) Composicion para el tratamiento de infecciones.
IT8321573A0 (it) Procedimento per la preparazione del meta-clorobenzotrifluoruro.